---
title: "Frazier Life Sciences Acquisition II Closes $75 Million IPO, Adds $25 Million Forward Purchase Backstop"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302020870.md"
description: "Frazier Life Sciences Acquisition II closed its $75 million IPO of 7.5 million Class A shares at $10.00 per share. The company executed multiple agreements, including an underwriting deal with Jefferies, a trust account setup, and registration rights for insiders. Additionally, it raised $3 million via private placement and secured a $25 million forward purchase commitment to support future business combinations."
datetime: "2026-10-15T20:33:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302020870.md)
  - [en](https://longbridge.com/en/news/302020870.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302020870.md)
generator: "portal-rs"
---

# Frazier Life Sciences Acquisition II Closes $75 Million IPO, Adds $25 Million Forward Purchase Backstop

Frazier Life Sciences Acquisition II completed a $75 million IPO of 7.5 million Class A shares at $10.00 per share and executed a suite of related agreements to support its SPAC strategy. The company signed an Underwriting Agreement with Jefferies, established a trust account to safeguard proceeds, granted registration rights to its sponsor and insiders, and raised $3 million via a concurrent private placement. It also secured a $25 million minimum forward purchase commitment to bolster funding at the time of its initial business combination, and put in place indemnification and governance agreements with directors, officers, and the sponsor.

**Agreement 1: Frazier Life Sciences Acquisition II Closes $75 Million IPO and Enters Underwriting Agreement With Jefferies**

-   **Agreement type**: Underwriting Agreement for IPO
-   **Counterparty**: Jefferies and other underwriters
-   **Signed / Effective**: Oct 13 2026 / Oct 13 2026
-   **Duration / Termination**: N/A
-   **Reason**: Execute and close the IPO

**Agreement 2: Frazier Life Sciences Acquisition II Establishes IPO Trust Account With Continental Stock Transfer & Trust**

-   **Agreement type**: Investment Management Trust Agreement
-   **Counterparty**: Continental Stock Transfer & Trust
-   **Signed / Effective**: Oct 13 2026 / Oct 13 2026
-   **Duration / Termination**: Until business combination or liquidation
-   **Reason**: Protect IPO proceeds pending a business combination

**Agreement 3: Frazier Life Sciences Acquisition II Grants Registration Rights to Sponsor and Insiders**

-   **Agreement type**: Registration Rights Agreement
-   **Counterparty**: Frazier Life Sciences Holdings II and certain officers and directors
-   **Signed / Effective**: Oct 13 2026 / Oct 13 2026
-   **Duration / Termination**: At will
-   **Reason**: Provide liquidity avenues for sponsor and insiders

**Agreement 4: Frazier Life Sciences Acquisition II Raises $3 Million Via Private Placement With Sponsor**

-   **Agreement type**: Private Placement Shares Purchase Agreement
-   **Counterparty**: Frazier Life Sciences Holdings II
-   **Signed / Effective**: Oct 13 2026 / Oct 13 2026
-   **Duration / Termination**: N/A
-   **Reason**: Supplement IPO proceeds and align sponsor incentives

**Agreement 5: Frazier Life Sciences Acquisition II Secures $25 Million Minimum Forward Purchase Commitment**

-   **Agreement type**: Forward Purchase Agreement (equity commitment)
-   **Counterparty**: Frazier Life Sciences Public Fund
-   **Signed / Effective**: Oct 13 2026 / Oct 13 2026
-   **Duration / Termination**: Until business combination closing
-   **Reason**: Enhance funding certainty for business combination

**Agreement 6: Frazier Life Sciences Acquisition II Enters Indemnification Agreements With Directors and Officers**

-   **Agreement type**: Indemnification Agreements for directors and officers
-   **Counterparty**: Company directors and officers
-   **Signed / Effective**: Oct 13 2026 / Oct 13 2026
-   **Duration / Termination**: At will
-   **Reason**: Support governance and attract qualified leadership

**Agreement 7: Frazier Life Sciences Acquisition II Signs Sponsor and Insider Letter on Voting and Transfer Restrictions**

-   **Agreement type**: Sponsor and Insider Letter Agreement
-   **Counterparty**: Frazier Life Sciences Holdings II and company directors and officers
-   **Signed / Effective**: Oct 13 2026 / Oct 13 2026
-   **Duration / Termination**: Until business combination or liquidation
-   **Reason**: Align incentives and govern pre-combination conduct

Original SEC Filing: Frazier Life Sciences Acquisition Corp. II \[ FLSC \] - 8-K - Oct. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [FLSC.US](https://longbridge.com/en/quote/FLSC.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)

## Related News & Research

- [Frazier Life Sciences Acquisition II Raises $78 Million in IPO and Private Placement](https://longbridge.com/en/news/302781770.md)
- [Top Executive Makes Bold Move with Major Stake in Life Sciences Firm](https://longbridge.com/en/news/302045349.md)
- [Nvidia has lost $2 trillion in value. Here's what options traders expect from earnings](https://longbridge.com/en/news/305815593.md)
- [BREAKINGVIEWS-Nine questions for Nvidia’s stand-in CEO](https://longbridge.com/en/news/305850075.md)
- [MPs ask what the break clause was for as Palantir wins two more years in the NHS](https://longbridge.com/en/news/305803837.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**